Penggunaan Isotretinoin Oral pada Tatalaksana Akne Vulgaris
DOI:
https://doi.org/10.55175/cdk.v48i4.66Kata Kunci:
Akne vulgaris, isotretinoin oralAbstrak
Akne vulgaris adalah penyakit kulit paling umum dan dikaitkan dengan kecemasan, penurunan harga diri, stigma, dan skar pada wajah yang dapat menjadi beban penyakit yang signifikan bagi pasien. Pada kasus akne nodulokistik dan papulopustular yang berat, isotretinoin oral sering diresepkan sebagai terapi lini pertama yang berpotensi menyembuhkan penyakit. Pedoman praktik klinis Kanada, Amerika, dan Eropa merekomendasikan isotretinoin untuk penatalaksanaan akne derajat sedang hingga berat. Meskipun penggunaan klinis isotretinoin telah berlangsung bertahun-tahun, tinjauan komprehensif terapi isotretinoin pada pasien akne masih kurang. Artikel ini akan memaparkan penggunaan isotretinoin oral pada tatalaksana akne vulgaris.
Acne vulgaris is the most common skin disease and the associated anxiety, reduced self-esteem, stigma, and facial scarring can impose a significant burden on the patient. In cases of severe nodulocystic and papulopustular acne, oral isotretinoin is often prescribed as a first-line treatment, potentially cure of disease. Canadian, American, and European clinical practice guidelines have suggested that isotretinoin should be used for management of moderate to severe acne. Despite many years of clinical use of isotretinoin, a comprehensive review of evidence for isotretinoin therapy for acne is lacking. This article describes the use of oral isotretinoin in the treatment of acne vulgaris.
Unduhan
Referensi
Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, et al. Oral isotretinoin for acne (Review). Cochrane Database of Systematic Reviews. 2018;Issue 11:1-199.
TanAU, SchlosserBJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Internat J Women’s Dermatol. 2018;4:56-71.
Faghihi G, Mokhtari F, Fard NM, Motamedi N, Hosseini SM. Comparing the efficacy of low dose and conventional dose of oral isotretinoin in treatment of moderate and severe acne vulgaris. J Res Pharm Pract. 2017;6(4):233-8.
Marron SE, Tomas-Aragones L, Boira S. Anxiety, depression, quality of life and patient satisfaction in acne patients treated with oral isotretinoin. Acta Derm Venereol. 2013;93:701-6.
Dhaked DR, Meena RS, Maheshwari A, Agarwal US, Purohit S. A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris. Indian Dermatol Online J. 2016;7(5):378-85.
LeydenJJ, Del RossoJQ, BaumEW. The use of isotretinoin in the treatment of acne vulgaris: Clinical considerations and future directions. J Clin Aesthetic Dermatol. 2014;7(2):S4-21.
BettoliV, Guerra-TapiaA, HeraneMI, Piquero-Martín J. Challenges and solutions in oral isotretinoin in acne: Reflections on 35 years of experience. Clinical, Cosmetic Investigational Dermatol. 2019;12:943-51.
Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment modalities for acne. Molecules. 2016;21(1063):1-20.
Oon HH, WongS, AwDCW, Cheong WK, Goh CL, Tan HH. Acne management guidelines by the dermatological society of Singapore. J Clin Aesthet Dermatol. 2019;12(7):34-50.
Vyas A, Sonker AK, Gidwani B. Carrier-based drug delivery system for treatment of acne. ScientWorld J. 2014;1-14.
Del RossoJQ. Face to face with oral isotretinoin. J Clin Aesthetic Dermatol. 2012;5(11):17-24.
Henry D, DormuthC, WinquistB, CarneyG, BugdenS, TeareG, et al. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ. 2016;188(10):723-30.
Bagatin E, de Freitas THP, Machado MCR, Ribeiro BM, Nunes S, da Rocha MAD. Adult female acne: A guide to clinical practice. An Bras Dermatol. 2019;94(1):62-75.
Layton A. The use of isotretinoin in acne. Dermato-Endocrinol. 2009;1(3):162-9.
BarbieriJS, SpaccarelliN, MargolisDJ, JamesWD. Approaches to limit systemic antibiotic use in acne: Systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments. J Am Acad Dermatol. 2019;80(2):538-49.
Melnik BC. Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017;97:173-81.
Choi JS, Koren G, NulmanI. Pregnancy and isotretinoin therapy. CMAJ. 2013;185(5):411-3.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.